Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438890 | 1.00 | TEAD1 (0.42) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL29438917 | 0.91 | TEAD1 (0.49) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL29438915 | 0.91 | TEAD1 (0.49) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL22718251 | 0.91 | TEAD1 (0.49) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL24496182 | 0.91 | TEAD1 (0.39) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL29648333 | 0.91 | TEAD1 (0.39) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL22718097 | 0.89 | TEAD1 (0.42) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL29438933 | 0.89 | TEAD1 (0.42) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL29438934 | 0.89 | TEAD1 (0.42) | TEAD1YAP1MEN1KMT2AKAT8 | |
| SCHEMBL24495997 | 0.89 | TSHR (0.38) | TEAD1YAP1MEN1KMT2AKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MEN1 3307/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MEN1 3307/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MEN1 3307/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MEN1 3307/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | TEAD1 7/4885YAP1 13/4885MEN1 3/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MEN1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.